Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.
- DOI
- 10.1016/j.ophtha.2026.08.039
- Published
- 2026 Sep 7
- Container
- Ophthalmology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ophtha.2026.08.039,
title = {Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.},
author = {Briceño CA and Idowu OO and Khong JJ and Kuenzel T and Tran AQ and Brittain C and Azumi A and Brockwell L and Ghadiri N and Coronel M and Ruf T and Li D and Salvi M and Garrido-Hermosilla AM and Barteselli G and Ortiz-Perez S and of the SatraGO-1 and SatraGO-2 investigators},
year = {2026},
journal = {Ophthalmology},
doi = {10.1016/j.ophtha.2026.08.039},
url = {https://doi.org/10.1016/j.ophtha.2026.08.039}
}RIS
TY - JOUR TI - Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials. AU - Briceño CA AU - Idowu OO AU - Khong JJ AU - Kuenzel T AU - Tran AQ AU - Brittain C AU - Azumi A AU - Brockwell L AU - Ghadiri N AU - Coronel M AU - Ruf T AU - Li D AU - Salvi M AU - Garrido-Hermosilla AM AU - Barteselli G AU - Ortiz-Perez S AU - of the SatraGO-1 and SatraGO-2 investigators PY - 2026 JO - Ophthalmology DO - 10.1016/j.ophtha.2026.08.039 UR - https://doi.org/10.1016/j.ophtha.2026.08.039 ER -
APA
CA, B., OO, I., JJ, K., T, K., AQ, T., C, B., A, A., L, B., N, G., M, C., T, R., D, L., M, S., AM, G., G, B., S, O., & investigators, O. T. S. A. S. (2026). Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.. Ophthalmology. https://doi.org/10.1016/j.ophtha.2026.08.039
Source records
- pubmed · retrieved 2026-09-26T06:28:38.214Z